Other mAbs directed to PSMA extracellular epitopes, as well as their conjugates, are being evaluated in a variety of experimental and preclinical models [23,24,25], but only IgGD2B [26], similarly to J591 [27], has been extensively characterized, demonstrating low tumor-to-blood ratios that can occur owing to relatively slow clearance of intact antibodies compared with fragments [28]. The gene discussed is FOLH1; the disease is neoplasm.